TY - JOUR
TI - Does the rare A172G mutation of PTPN11 gene convey a mild Noonan syndrome phenotype?
AU - Kitsiou-Tzeli, S.
AU - Papadopoulou, A.
AU - Kanaka-Gantenbein, C.
AU - Fretzayas, A.
AU - Daskalopoulos, D.
AU - Kanavakis, E.
AU - Nicolaidou, P.
JO - Frontiers of Hormone Research
PY - 2006
VL - 66
TODO - 3
SP - 124-131
PB - 
SN - null
TODO - 10.1159/000094145
TODO - alanine;  asparagine;  aspartic acid;  glycine, amino acid substitution;  article;  autosomal dominant disorder;  case report;  clinical feature;  congenital heart disease;  correlation analysis;  cryptorchism;  diagnostic value;  disease classification;  disease severity;  exon;  face dysmorphia;  gene;  gene identification;  gene mutation;  genetic disorder;  genotype;  human;  male;  missense mutation;  molecular model;  Noonan syndrome;  phenotype;  point mutation;  prediction;  priority journal;  psychomotor retardation;  PTPN11 gene;  rare disease;  school child;  short stature, Adult;  Amino Acid Substitution;  Child;  Exons;  Female;  Growth Disorders;  Humans;  Intracellular Signaling Peptides and Proteins;  Male;  Middle Aged;  Noonan Syndrome;  Phenotype;  Point Mutation;  Protein-Tyrosine-Phosphatase
TODO - Background: Noonan syndrome (NS) (OMIM 163950) is an autosomal dominant developmental disorder characterized mainly by typical facial dysmorphism, growth retardation and variable congenital heart defects. In unrelated individuals with sporadic or familial NS, heterozygous missense point mutations in the gene PTPN11 (OMIM 176876) have been confirmed, with a clustering of mutations in exons 3 and 8, the mutation A922G (Asn308Asp) accounting for nearly 25% of cases. Patient and Methods: We report a 7-year-old boy with short stature and some other clinical features of NS, who has been investigated by molecular analysis for the presence of mutations in the PTPN11 gene. Result: The de novo mutation A172G in the exon 3 of the PTPN11 gene, predicting an Asn58Asp substitution, has been found. To the best of our knowledge, this specific mutation has only been described once before, but this is the first report of detailed clinical data suggesting a mild phenotype. Conclusion: Detailed clinical phenotype in every patient with major or minor features of NS and molecular identification of PTPN11 gene mutation may contribute to a better phenotype-genotype correlation. Copyright © 2006 S. Karger AG.
ER -